The Six Genes Behind Gluten Sensitivity: Beyond HLA-DQ2 and DQ8

Ask most people about celiac genetics, and you’ll hear two names: HLA-DQ2 and HLA-DQ8. These are the headline genes — the ones your gastroenterologist tests for, the ones 23andMe reports on, the ones that get all the attention. And they deserve it. Without at least one of these genes, celiac disease is essentially impossible.

But here’s what that narrative misses: roughly 30-40% of the population carries HLA-DQ2 or HLA-DQ8, yet only about 3% of carriers ever develop celiac disease. Something else is determining who actually gets sick. And for the estimated 6% of Americans with non-celiac gluten sensitivity — a condition that doesn’t require HLA genes at all — the genetic picture is even murkier.

Researchers have spent the last two decades searching for the other genetic factors that tip the scales. What they’ve found is a network of genes that influence intestinal permeability, immune activation, inflammatory signaling, and tissue repair — all working together with HLA genes to determine your individual gluten response. We’ve been tracking this research closely, and the emerging picture is far more complex and fascinating than the simple “DQ2 or DQ8” story.

In this article, we’ll walk through six genetic factors beyond HLA-DQ2 and DQ8 that shape gluten sensitivity — what they do, how they interact, and what this means for testing and management.

Key Takeaways

• HLA-DQ2 and DQ8 are necessary but not sufficient for celiac disease — additional genes help determine which carriers actually develop the condition.
• At least six other genetic regions influence gluten sensitivity, affecting intestinal barrier function, immune regulation, inflammatory response, and tissue repair.
• Non-celiac gluten sensitivity likely involves a different set of genes entirely, which is why it doesn’t require HLA-DQ2 or DQ8.
• Current consumer genetic tests only cover HLA genes — they miss the broader genetic picture, which means a “low risk” result can be misleading.
• Understanding your full genetic profile can help you and your healthcare provider make more informed decisions about monitoring, testing frequency, and nutritional support.

A Quick Refresher: Why HLA-DQ2 and DQ8 Matter

Before diving into the supporting cast, let’s quickly recap why HLA-DQ2 and HLA-DQ8 are the leads. These genes encode proteins on the surface of your immune cells — specifically, proteins that present fragments of digested food to your T cells for inspection. In most people, gluten fragments pass through this checkpoint without incident. But HLA-DQ2 and HLA-DQ8 proteins have a unique shape that happens to bind gluten peptides extremely well.

When an HLA-DQ2 or DQ8 molecule grabs a gluten fragment and shows it to a T cell, it can trigger an aggressive immune response — the autoimmune attack on the intestinal lining that defines celiac disease. No other HLA variants bind gluten this effectively, which is why these two genes are considered the gatekeepers of celiac risk.

About 90-95% of celiac patients carry HLA-DQ2 (specifically the DQ2.5 variant), and most of the remaining 5-10% carry HLA-DQ8. A tiny fraction (under 1%) carry neither, and these rare cases are still being studied. For a deeper look at these genes, see our detailed guide to HLA-DQ2 and DQ8.

But HLA genes explain who can get celiac — not who will. That’s where the other genes come in.

The Six Key Genetic Players in Gluten Sensitivity

Genome-wide association studies (GWAS) — massive research projects that scan the entire genome across thousands of people — have identified over 40 non-HLA genetic regions associated with celiac disease. We’ve distilled these down to six of the most well-characterized and clinically relevant.

1. CTLA-4 (Cytotoxic T-Lymphocyte Associated Protein 4)

What it does: CTLA-4 is an immune checkpoint gene — essentially a brake pedal for T cell activation. When functioning normally, CTLA-4 helps prevent your immune system from overreacting to harmless substances, including food proteins.

How it relates to gluten: Certain variants of CTLA-4 reduce the effectiveness of this braking system. Research published in the Journal of Autoimmunity has shown that specific CTLA-4 polymorphisms are significantly more common in celiac patients compared to healthy controls — even after accounting for HLA status. When the brake is weaker, the immune response to gluten can escalate more easily.

Why it matters: CTLA-4 variants are also associated with other autoimmune conditions, including Type 1 diabetes, autoimmune thyroid disease, and rheumatoid arthritis. This may explain why celiac disease frequently co-occurs with these conditions — they share common genetic immune dysregulation.

2. IL-21 (Interleukin-21)

What it does: IL-21 is a cytokine gene — it encodes a signaling molecule that amplifies immune responses. IL-21 activates natural killer cells, promotes B cell antibody production, and enhances T cell activity.

How it relates to gluten: The IL-21 gene region (specifically the IL-2/IL-21 locus on chromosome 4) was one of the first non-HLA regions identified in celiac GWAS. Studies have found that intestinal tissue from celiac patients shows markedly elevated IL-21 levels during active disease. Variants in the regulatory regions of this gene may predispose certain individuals to produce more IL-21 in response to gluten, amplifying the inflammatory cascade.

Why it matters: IL-21 is considered a potential therapeutic target. Several pharmaceutical companies are investigating whether blocking IL-21 signaling could reduce gluten-triggered inflammation — though no such treatment is available yet.

3. MYO9B (Myosin IXB)

What it does: MYO9B encodes a protein involved in maintaining the tight junctions between intestinal epithelial cells. These tight junctions are the seals that control what passes through the intestinal wall into the bloodstream.

How it relates to gluten: Variants in MYO9B have been associated with increased intestinal permeability — sometimes called “leaky gut” in popular health discussions, though gastroenterologists prefer the term “increased intestinal permeability.” When tight junctions are compromised, larger molecules — including incompletely digested gluten peptides — can cross the intestinal barrier and encounter immune cells that wouldn’t normally see them.

Why it matters: MYO9B may be particularly relevant to non-celiac gluten sensitivity (NCGS), which doesn’t involve the HLA-mediated autoimmune pathway but does involve intestinal barrier dysfunction. People with NCGS-associated MYO9B variants might react to gluten not because their immune system targets it specifically, but because their intestinal barrier lets too much through.

4. SH2B3 (SH2B Adaptor Protein 3)

What it does: SH2B3 (also known as LNK) is an adaptor protein involved in signaling pathways that regulate immune cell development and function. It helps control the proliferation and activation of multiple immune cell types.

How it relates to gluten: A specific variant in SH2B3 (rs3184504) has been consistently associated with celiac disease across multiple large-scale studies. This variant affects how immune cells respond to activation signals, potentially lowering the threshold at which gluten triggers an inflammatory response. The same variant is associated with increased white blood cell counts and other markers of immune activation.

Why it matters: SH2B3 is one of the most replicated non-HLA associations with celiac disease, lending high confidence to its role. It’s also associated with cardiovascular risk and other autoimmune conditions, highlighting the interconnected nature of genetic immune regulation.

5. TAGAP (T-Cell Activation RhoGTPase Activating Protein)

What it does: TAGAP is involved in the final stages of T cell activation — specifically, the cytoskeletal rearrangement that T cells need to carry out their functions, including migrating to sites of inflammation and interacting with target cells.

How it relates to gluten: GWAS data shows that TAGAP variants are significantly enriched in celiac patients. By affecting how efficiently T cells mobilize after activation, TAGAP variants may influence how vigorously the immune system responds once HLA-DQ2 or DQ8 presents gluten to T cells. Think of it as controlling the speed at which immune cells arrive at the scene once the alarm is triggered.

Why it matters: TAGAP is also associated with Crohn’s disease and multiple sclerosis, making it another shared autoimmune gene. For families with multiple autoimmune conditions, TAGAP variants may be part of the common genetic thread.

6. MTHFR (Methylenetetrahydrofolate Reductase)

What it does: MTHFR converts dietary folate into its active form, methylfolate, which is essential for DNA methylation, neurotransmitter production, and cellular repair. While not a classic “celiac gene,” MTHFR variants significantly impact how well people with gluten-related conditions recover and manage their health.

How it relates to gluten: Celiac disease causes malabsorption of folate and B vitamins — the very nutrients MTHFR needs as raw materials. When someone has both celiac disease and an MTHFR variant (particularly C677T, which reduces enzyme efficiency by up to 70% in homozygous carriers), the combined effect can significantly impair methylation, DNA repair, and neurological function. This may explain why some celiac patients experience persistent symptoms — fatigue, brain fog, mood issues — even after intestinal healing.

Why it matters: Unlike the other genes on this list, MTHFR is actionable today. If you know you carry an MTHFR variant alongside celiac disease, you can switch to methylfolate supplements, optimize B12 intake, and support methylation pathways directly. For a complete guide, see our MTHFR Supplement Guide.

How These Genes Work Together

None of these genes work in isolation. The reason celiac disease and gluten sensitivity are so complex is that they involve a cascade of events, with different genes influencing each step:

This is why two people with identical HLA-DQ2 status can have dramatically different celiac experiences. One might have “helpful” variants at CTLA-4, IL-21, and MYO9B that keep the immune response restrained and the intestinal barrier intact. The other might have “unhelpful” variants at multiple points in the cascade, creating a perfect storm for severe disease.

What This Means for Genetic Testing

Current consumer genetic tests (23andMe, AncestryDNA) and most clinical celiac panels test only for HLA-DQ2 and HLA-DQ8. They don’t screen for CTLA-4, IL-21, MYO9B, SH2B3, TAGAP, or MTHFR variants. This means today’s genetic tests can tell you whether celiac disease is possible — but they can’t tell you how likely it is.

This creates two important limitations:

• False reassurance from negative HLA results — A person without HLA-DQ2 or DQ8 is very unlikely to develop celiac disease, but they could still have non-celiac gluten sensitivity driven by genes like MYO9B. A “negative” genetic test doesn’t mean gluten can’t cause symptoms.
• Uncertainty from positive HLA results — A positive test means celiac is possible, but since 97% of carriers never develop it, a positive result alone has limited predictive power. The additional genes discussed in this article would improve risk stratification — but they’re not yet part of standard testing.

The future of celiac genetic testing likely involves polygenic risk scores — calculations that combine your variants across dozens of genes to generate a more accurate individual risk estimate. Several research groups are developing these scores, but they haven’t reached clinical practice yet.

Our Top Picks: Products for Understanding and Managing Your Genetic Risk

Products to Approach with Caution

• Raw DNA data interpretation services with no medical oversight — Sites that let you upload raw genetic data and generate health reports can provide interesting but often misleading information. Without proper clinical context, individual gene variants can be over- or under-interpreted. Always discuss genetic findings with a healthcare provider or genetic counselor.
• “Comprehensive gut gene” panels from unaccredited labs — Some direct-to-consumer companies offer “gut genetics” panels testing dozens of genes related to digestion. If the lab isn’t CLIA-certified or the test isn’t FDA-cleared, the accuracy and clinical relevance may be questionable. Stick with established testing services.

Common Mistakes When Interpreting Genetic Risk for Gluten Sensitivity

• Treating HLA-negative results as a clean bill of health — No HLA-DQ2 or DQ8 essentially rules out celiac disease, but it does not rule out non-celiac gluten sensitivity. If you have symptoms, pursue further evaluation regardless of HLA status.
• Assuming genetic risk equals genetic destiny — Even the highest-risk genetic combination (homozygous HLA-DQ2.5 with unfavorable variants at CTLA-4, IL-21, and other loci) doesn’t guarantee celiac disease. Risk factors stack the odds, but environmental triggers and epigenetic factors ultimately determine outcomes.
• Ignoring MTHFR in the celiac context — Many people think of MTHFR as separate from celiac genetics. But impaired methylation from MTHFR variants directly affects the DNA repair and epigenetic processes that influence celiac disease expression and recovery. Test for both.
• Skipping antibody testing because genetic testing was done — Genetic testing tells you about risk. Antibody testing (tTG-IgA) tells you about current disease activity. You need both for a complete picture. A positive gene with negative antibodies means “possible but not active.” A positive gene with positive antibodies means “likely active — get a biopsy.”
• Testing family members only once — Celiac can develop at any age. The American College of Gastroenterology recommends periodic re-screening of at-risk family members every 2-3 years, because a negative antibody test today doesn’t guarantee a negative test in five years.

Frequently Asked Questions

The Science Is Catching Up to What Your Body Already Knows

Here’s what I find most validating about the research behind these six genes: it confirms what so many of us have felt intuitively. That celiac and gluten sensitivity aren’t as simple as one gene, one test, one answer. That two people with the same HLA status can have completely different experiences. That reacting to gluten without a positive celiac panel doesn’t make you a hypochondriac — it might mean your MYO9B or your CTLA-4 is telling a story that the standard tests aren’t designed to hear yet.

We’re not at the point where your doctor can order a “complete gluten gene panel” that tests all six of these factors. That’s coming — polygenic risk scores are being developed right now — but it’s not here yet. What is here today is MTHFR testing, which is the most actionable gene on this list. If you have celiac and you haven’t checked your MTHFR status, that’s a concrete step you can take this week. Our MTHFR Supplement Guide will tell you exactly what to do with the results.

And if you tested HLA-negative but still react to gluten? You’re not imagining it. Genes like MYO9B work through entirely different pathways. Keep advocating for yourself, keep working with a provider who listens, and know that the science is slowly building the explanation your body has been giving you all along.

Ready to cover your nutritional bases? Download our free GF Nutrition Cheat Sheet — it maps the nutrients that support every gene discussed in this article, from methylation to gut barrier repair.